Acanthosis Nigricans revisitada
Palavras-chave:
Acanthosis nigricans, síndroma paraneoplásica, insulinorresistência, diabetes mellitus não insulinodependenteResumo
A acanthosis nigricans é uma dermatose referida frequentemente como síndroma paraneoplásica ou manifestação de ínsulinorresistêncía. Encarada como raridade, poucas vezes o clínico com ela contacta. Os autores apresentam uma revisão acerca desta manifestação cutânea, procurando uma abordagem que permita a sua detecção e correcta valorização por parte do clínico.
Downloads
Referências
Esteves JA, Baptista AP. Rodrigo FG, Gomes MAM. Dermatologia. 2' Ed. F. Calouste Gulbenkian 1992: 732-734.
Matsuoka LY, Wortsman J. Goldman J. Acanthosis nigricans. Clin Dennatol 1993; 11: 21-25.
Houpl KR, Cruz PD. Acanthosis Nigricans. ln. Freedberg et al, eds. Fitzpatrick '.1· Dermatology in General Medicine. 5th ed. McGraw Hill 1999; 2121-2125.
Kurzrock R. Cohen PR. Cutaneous Paraneoplastic Syndromes in Solid Tumors. Am J Med 1995: 662-671
Anderson SHC, Hudson-Peacock M, Muller AF. Malignant acanthosis nigricans: potencial role of chemotherapy. Br J Dermatol 1999; 141: 714-716.
Sedano HO, Gorlin RJ. Acanthosis nigricans. Oral Surg Oral Med Oral Pathol 1987; 63: 462-467.
Tyler MT, Ficarra G, Silverman SJ et ai. Malignant acanthosis nigricans with florid papillary oral lesions. Oral Surg Oral Med Oral Pathol 1996; 81: 445-449.
Matsuoka LY, Wortsman J, Gavin JR et al. Spectrum of endocrine abnormalities associated with acanthosis nigricans. Am J Med 1987; 83: 719-725.
Hernández-Perez E. On the Classification of Acanthosis Nigricans. Am J Dermatol 1984; 11: 605-606.
Burke JP, Duggirala R, Hale DE et ai. Genetic basis of acanthosis nigricans in Mexican Americans and its association with phenotypes related to type 2 diabetes. Human Genetics 2000; 106: 467-472.
Moller DE, Flier JS. lnsulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48.
Kahn CR, Flier JS, Bar RS et al. The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med 1976; 294: 739-745.
Stuart CA, Smith MM, Gilkison CR et ai. Acanthosis Nigricans among Native Americans: An lndicator of High Diabetes Risk. Am J Public Health 1994; 84: 1839-1842.
Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989; 87: 269-272.
Stuart CA, Gilkinson CR, Smith MM et ai. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr l 998; 37 (2): 73-79.
Jones, KL. Non-insulin dependent diabetes in children and adolescent: therapeutic challenge. Clin Pediatr 1998; 37 (2): 103-
Scott CR. Smith JM, Cradock MM et al. Characteristics of youth onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus ai diagnosis. Pediatrics 1997; 100: 84-91.
Hud JA, Cohen JB, Wagner JM et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992: 128: 941-944.
Curth HO, Wilberg AW, Machachek GF. The site and histology associated with acanthosis nigricans. Cancer 1962; 15: 364-382.
Burke JP, Hale DE, Hazuda HP et al. A quantitative scale for acanthosis nigricans. Diabetes Care 1999; 22: 1655-1659.
Baker H, Barth JH. Acanthosis nigricans. Br J Dermatol 1983; 109 (24): 101-103.
Dhar S, Dawn G, Kanwar AJ et ai. Familiai acanthosis nigricans. Am J Dermatol 1996; 35: 126-127.
Downs AMR, Kennedy CTC. Somatotrophin-induced acanthosis nigricans. Br J Dermatol 1999; 141: 390-391.
Baird JS, Johnson JL, Elliot Mills D et ai. Systemic lupus erithematosus with acanthosis nigricans, hyperpigmentation and receptor antibody. Lupus 1997; 6 (3): 275-278.
Matsuoka LY, Goldman J, Wortsman J. Antibodies against the insulin receptor in paraneoplastic acanthosis nigricans. Am J Med 1987; 82: 1253-1256.
Ellis DL, Kafka SP, Chow JC et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat and multiple acrochordons. N Engl J Med 1987; 317: 1582-1587.
Koyama S, Ikedo K, Sato M et al. Transforming growth factor alpha (TGF-alpha) producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J. Gastroenterol 1997; 32: 71-77.
Erikson JW. Is hyperinsulinemia the cause of acanthosis nigricans in the type B syndrome of insulin resistance? Diabetes Care 1997; 20: 1045.
Panidis D, Skiadopoulos S, Rousso D et al. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol 1995; 132: 936-941.
Kuzuya H, Matsuura N, Sakamoto M et al. Trial of Insulinlike Growth Factor I Therapy for Patients With Extreme Insutin Resistance Syndromes. Diabetes 1993; 42: 696-705.
Kuroki R, Sadamoto Y, Imamura M et al. Acanthosis nigricans with Severe Obesity, lnsulin Resistance and Hypothyroidism: lmprovement by Diet Contrai. Dermatology 1999; 198: 164-166.
Lunetta M, Di Mauro M, Le Moli R, Burrafato S. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J. Endocrinol lnvest 1996; 19: 699-703.
Akovbyan VA, Talanin NY, Arifov SS et al. Successful treatment of acanthosis nigricans with etretinate. J Am Acad Dermatol 1994; 31: 118-120.
Fagot-Campagna A, Pettit DJ, Engelgau MM et ai. Type 2 diabetes among North American Children and adolescents: an epidemio!ogic review and a public health perspective. J Pediatr 2000; 136 (5): 664-672.
Ehtisham S, Barret TG, Shaw NJ. Type 2 diabetes mellitus in UK children- an emerging problem. Diabetic Medicine 2000; 17: 867-
American Diabetes Association. Type 2 Diabetes in Children and Adolescents. Pediatrics 2000; 105: 671-680.
Dean, H. Diagnostic Criteria for Non-Insulin Dependent Diabetes in Youth (NIDDM-Y). Clin Pediatr 1998; 37 (2): 67-71.
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
